NCT02959437 2025-10-21
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
Incyte Corporation
Phase 1/2 Terminated
Clinical Trials
3 trialsNCT02265510 2020-04-17
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT00384956 2016-12-12
A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes
Washington University School of Medicine
Phase 2 Completed